Francois Nader - Nov 19, 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role: Director
Signature: /s/ Adam M. Veness, as attorney-in-fact for Francois Nader
Stock symbol: XLRN
Transactions as of: Nov 19, 2021
Transactions value $: $0
Form type: 4
Date filed: 11/22/2021, 08:06 AM
Previous filing: Jul 23, 2021
Next filing: Dec 16, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLRN	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction		-6.75K	-100%		0	Nov 19, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-10K	-100%	Nov 19, 2021	Common Stock	10K	$27.97	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-7.5K	-100%	Nov 19, 2021	Common Stock	7.5K	$30.17	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-10K	-100%	Nov 19, 2021	Common Stock	10K	$34.14	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-7.5K	-100%	Nov 19, 2021	Common Stock	7.5K	$40.61	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-576	-100%	Nov 19, 2021	Common Stock	576	$41.20	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-20K	-100%	Nov 19, 2021	Common Stock	20K	$41.48	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-7.5K	-100%	Nov 19, 2021	Common Stock	7.5K	$41.64	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-8.19K	-100%	Nov 19, 2021	Common Stock	8.19K	$52.99	Direct	F2
transaction	XLRN	Option to Purchase Common Stock	Disposed to Issuer	-3.22K	-100%	Nov 19, 2021	Common Stock	3.22K	$115.53	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Francois Nader is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2	Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Content

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.